Eli Lilly has agreed to acquire Centessa Pharmaceuticals for up to $7.8 billion, consisting of an upfront cash payment of $38 per share that values Centessa at roughly $6.3 billion, plus up to $1.5 billion in contingent value rights tied to regulatory and commercial milestones for the company’s orexin‑receptor‑2 agonist cleminorexton (ORX750). The deal is expected to close in the third quarter of 2026 once regulatory approvals and shareholder consent are obtained.
The acquisition expands Lilly’s neuroscience portfolio into the high‑margin sleep‑wake disorder market, where narcolepsy, narcolepsy type 2, and idiopathic hypersomnia represent a multi‑billion‑dollar opportunity that has remained largely untapped. By adding cleminorexton, Lilly gains a best‑in‑class candidate that could become a new revenue driver and reduce its reliance on the obesity‑driven growth engine of Mounjaro and Zepbound.
Lilly’s recent earnings underscore the strategic fit of the deal. In Q4 2025, the company reported $19.3 billion in revenue, a 43 % year‑over‑year increase driven by strong demand for its GLP‑1 products, and an EPS of $7.39. The acquisition is positioned to complement this momentum by diversifying the revenue mix and providing a new growth engine that could offset the plateauing of its core obesity portfolio.
The OX2R agonist space is competitive, with Takeda’s oveporexton slated for an FDA decision in Q3 2026 and Alkermes also developing an OX2R agonist. By securing cleminorexton, Lilly gains a first‑mover advantage in a market where regulatory approval is still pending for most candidates, potentially positioning it ahead of competitors in a rapidly expanding therapeutic area.
Lilly executives emphasized that the acquisition aligns with the company’s long‑term strategy to broaden its neuroscience footprint and capture unmet medical needs. They highlighted the potential for cleminorexton to address a sizable patient population that currently has limited treatment options, reinforcing Lilly’s commitment to innovation beyond its core obesity and diabetes businesses.
The contingent value rights structure caps the upfront cost while tying additional payments to the successful regulatory and commercial performance of cleminorexton, thereby managing financial risk. If the candidate achieves FDA approval before January 1 2030, Lilly could receive up to $1.5 billion in additional payments, which would significantly boost the company’s revenue prospects in the sleep‑wake disorder market and enhance its competitive positioning against rivals such as Takeda and Alkermes.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.